{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=insulin+glargine+HOE901&page=3",
    "query": {
      "intervention": "insulin glargine HOE901",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 304,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=insulin+glargine+HOE901&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=insulin+glargine+HOE901&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T23:08:06.380Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02843399",
      "title": "Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 15498,
      "start_date": "2016-08-15",
      "completion_date": "2016-12-15",
      "has_results": false,
      "last_update_posted_date": "2017-12-15",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02843399"
    },
    {
      "nct_id": "NCT03170544",
      "title": "Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "MK-1092, 4.0 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 8.0 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 16 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 32 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 64 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "Glargine 3.0 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "Lispro 1.2 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to glargine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to MK-1092",
          "type": "DRUG"
        },
        {
          "name": "Dextrose",
          "type": "OTHER"
        },
        {
          "name": "Insulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 69,
      "start_date": "2017-08-16",
      "completion_date": "2018-11-08",
      "has_results": true,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170544"
    },
    {
      "nct_id": "NCT00976391",
      "title": "A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "albiglutide + insulin glargine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "insulin glargine + preprandial lispro insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 586,
      "start_date": "2009-09",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 142,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Gilbert, Arizona + 119 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00976391"
    },
    {
      "nct_id": "NCT00135096",
      "title": "Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin glulisine",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 345,
      "start_date": "2004-08",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2011-01-11",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135096"
    },
    {
      "nct_id": "NCT02556918",
      "title": "Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Regular Human Insulin",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Supplemental insulin (Insulin lispro)",
          "type": "DRUG"
        },
        {
          "name": "Supplemental insulin (Insulin aspart)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 202,
      "start_date": "2016-01",
      "completion_date": "2018-11-06",
      "has_results": true,
      "last_update_posted_date": "2019-12-23",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02556918"
    },
    {
      "nct_id": "NCT01079234",
      "title": "Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 493,
      "start_date": "2010-03",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2017-02-09",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 40,
      "location_summary": "Encino, California • Fresno, California • Huntington Beach, California + 34 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01079234"
    },
    {
      "nct_id": "NCT03874715",
      "title": "Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin Aspart SAR341402",
          "type": "DRUG"
        },
        {
          "name": "Insulin Aspart",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine U100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2019-03-11",
      "completion_date": "2020-07-08",
      "has_results": true,
      "last_update_posted_date": "2024-04-17",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 33,
      "location_summary": "Concord, California • Temecula, California • Ventura, California + 30 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Temecula",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03874715"
    },
    {
      "nct_id": "NCT00309244",
      "title": "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Technosphere® Insulin Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 677,
      "start_date": "2006-02",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-10-16",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 80,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00309244"
    },
    {
      "nct_id": "NCT05662332",
      "title": "A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "T2D"
      ],
      "interventions": [
        {
          "name": "Insulin Efsitora Alfa",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 795,
      "start_date": "2023-01-14",
      "completion_date": "2024-07-19",
      "has_results": true,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Sheffield, Alabama • Escondido, California + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Gardena",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05662332"
    },
    {
      "nct_id": "NCT01768559",
      "title": "Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Lixisenatide (AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Insulin glulisine QD",
          "type": "DRUG"
        },
        {
          "name": "Insulin glulisine TID",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine (Mandatory background drug)",
          "type": "DRUG"
        },
        {
          "name": "Metformin (Background drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 894,
      "start_date": "2013-01",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-01-04",
      "last_synced_at": "2026-10-07T23:08:06.380Z",
      "location_count": 46,
      "location_summary": "Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01768559"
    }
  ]
}